Drug Profile


Alternative Names: B663; LAM320; Lamprene

Latest Information Update: 11 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University College Dublin
  • Developer Alliance Pharma plc; Novartis; University College Dublin; University of Pretoria
  • Class Antibacterials; Antileprotics; Phenazines
  • Mechanism of Action Adenosine triphosphatase inhibitors; DNA inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leprosy
  • Phase II/III Tuberculosis
  • Discontinued Acinetobacter infections; Liver cancer

Most Recent Events

  • 03 Apr 2017 Novartis intends to submit NDA to the US FDA for Tuberculosis in 2018
  • 11 Feb 2016 Phase-II/III clinical trials in Tuberculosis in Lithuania (PO) (EudraCT2015-004440-19)
  • 01 Apr 2003 No development reported - Phase-II for Liver cancer in South Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top